(SPA) Société de de - Ratings and Ratios
Mineral Water, Sparkling Water, Beverages
Description: SPA Société de de
Spadel SA is a Belgian company that specializes in producing and marketing natural mineral water under various brand names, including Spa, Bru, Wattwiller, Carola, and Devin. As a subsidiary of Finances Et Industries Sa, Spadel operates in the Soft Drinks & Non-alcoholic Beverages industry.
To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth, market share, and brand recognition are essential. A strong brand portfolio like Spadels can contribute to customer loyalty and retention. Additionally, the companys return on equity (RoE) of 19.41% indicates a relatively high return on shareholders investment. Other relevant KPIs could include sales volume, average selling price, and operating margins.
From a valuation perspective, Spadels price-to-earnings (P/E) ratio of 19.90 suggests that the stock is trading at a reasonable multiple relative to its earnings. To further assess the companys valuation, metrics such as enterprise value-to-EBITDA (EV/EBITDA) and dividend yield could be considered. A thorough analysis of Spadels financial statements and industry trends would be necessary to determine the companys intrinsic value.
As a Trading Analyst, its crucial to monitor Spadels stock performance and trading activity. While the current stock price is €197.00, the 52-week high and low prices are €202.00 and €145.03, respectively. This information, combined with technical indicators like moving averages and average true range, can help identify potential trading opportunities.
SPA Stock Overview
| Market Cap in USD | 1,021m |
| Sub-Industry | Soft Drinks & Non-alcoholic Beverages |
| IPO / Inception |
SPA Stock Ratings
| Growth Rating | 40.4 |
| Fundamental | 82.4% |
| Dividend Rating | 40.5 |
| Rel. Strength | -5.81 |
| Analysts | - |
| Fair Price Momentum | 192.64 EUR |
| Fair Price DCF | 786.21 EUR |
SPA Dividends
| Dividend Yield 12m | 1.15% |
| Yield on Cost 5y | 1.24% |
| Annual Growth 5y | 1.92% |
| Payout Consistency | 87.7% |
| Payout Ratio | 55.2% |
SPA Growth Ratios
| Growth Correlation 3m | 70% |
| Growth Correlation 12m | 86.3% |
| Growth Correlation 5y | 32.9% |
| CAGR 5y | 4.78% |
| CAGR/Max DD 5y | 0.23 |
| Sharpe Ratio 12m | -0.10 |
| Alpha | 28.05 |
| Beta | -0.008 |
| Volatility | 33.02% |
| Current Volume | 0k |
| Average Volume 20d | 0k |
| Stop Loss | 195.9 (-3%) |
| Signal | -0.43 |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (56.4m TTM) > 0 and > 6% of Revenue (6% = 37.9m TTM) |
| FCFTA 0.25 (>2.0%) and ΔFCFTA 18.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 16.81% (prev 13.73%; Δ 3.08pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.34 (>3.0%) and CFO 158.8m > Net Income 56.4m (YES >=105%, WARN >=100%) |
| Net Debt (-144.7m) to EBITDA (104.4m) ratio: -1.39 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (4.15m) change vs 12m ago 0.01% (target <= -2.0% for YES) |
| Gross Margin 20.45% (prev 15.32%; Δ 5.13pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 141.1% (prev 120.6%; Δ 20.50pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 15.10 (EBITDA TTM 104.4m / Interest Expense TTM 4.50m) >= 6 (WARN >= 3) |
Altman Z'' 4.33
| (A) 0.23 = (Total Current Assets 235.2m - Total Current Liabilities 129.0m) / Total Assets 470.9m |
| (B) 0.55 = Retained Earnings (Balance) 259.5m / Total Assets 470.9m |
| (C) 0.15 = EBIT TTM 68.0m / Avg Total Assets 447.9m |
| (D) 0.03 = Book Value of Equity 5.00m / Total Liabilities 160.4m |
| Total Rating: 4.33 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 82.40
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 15.56% = 5.0 |
| 3. FCF Margin 18.60% = 4.65 |
| 4. Debt/Equity 0.11 = 2.49 |
| 5. Debt/Ebitda 0.32 = 2.42 |
| 6. ROIC - WACC 12.58% = 12.50 |
| 7. RoE 19.41% = 1.62 |
| 8. Revenue Trend data missing |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend 38.35% = 0.96 |
| 11. EPS CAGR -1.91% = -0.24 |
What is the price of SPA shares?
Over the past week, the price has changed by -1.94%, over one month by +2.54%, over three months by +2.13% and over the past year by +11.62%.
Is Société de de a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SPA is around 192.64 EUR . This means that SPA is currently overvalued and has a potential downside of -4.63%.
Is SPA a buy, sell or hold?
What are the forecasts/targets for the SPA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 209.6 | 3.7% |
SPA Fundamental Data Overview
Market Cap EUR = 871.9m (871.9m EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 149.9m EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 20.404
P/S = 2.2984
P/B = 2.6745
Beta = 0.272
Revenue TTM = 631.9m EUR
EBIT TTM = 68.0m EUR
EBITDA TTM = 104.4m EUR
Long Term Debt = 31.4m EUR (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 1.86m EUR (from shortTermDebt, last quarter)
Debt = 33.3m EUR (Calculated: Short Term 1.86m + Long Term 31.4m)
Net Debt = -144.7m EUR (from netDebt column, last quarter)
Enterprise Value = 755.3m EUR (871.9m + Debt 33.3m - CCE 149.9m)
Interest Coverage Ratio = 15.10 (Ebit TTM 68.0m / Interest Expense TTM 4.50m)
FCF Yield = 15.56% (FCF TTM 117.5m / Enterprise Value 755.3m)
FCF Margin = 18.60% (FCF TTM 117.5m / Revenue TTM 631.9m)
Net Margin = 8.93% (Net Income TTM 56.4m / Revenue TTM 631.9m)
Gross Margin = 20.45% ((Revenue TTM 631.9m - Cost of Revenue TTM 502.7m) / Revenue TTM)
Tobins Q-Ratio = 151.1 (set to none) (Enterprise Value 755.3m / Book Value Of Equity 5.00m)
Interest Expense / Debt = 0.81% (Interest Expense 268.0k / Debt 33.3m)
Taxrate = 20.42% (from yearly Income Tax Expense: 10.5m / 51.6m)
NOPAT = 54.1m (EBIT 68.0m * (1 - 20.42%))
Current Ratio = 1.82 (Total Current Assets 235.2m / Total Current Liabilities 129.0m)
Debt / Equity = 0.11 (Debt 33.3m / last Quarter total Stockholder Equity 310.4m)
Debt / EBITDA = 0.32 (Net Debt -144.7m / EBITDA 104.4m)
Debt / FCF = 0.28 (Debt 33.3m / FCF TTM 117.5m)
Total Stockholder Equity = 290.7m (last 4 quarters mean)
RoA = 11.98% (Net Income 56.4m, Total Assets 470.9m )
RoE = 19.41% (Net Income TTM 56.4m / Total Stockholder Equity 290.7m)
RoCE = 21.12% (Ebit 68.0m / (Equity 290.7m + L.T.Debt 31.4m))
RoIC = 18.38% (NOPAT 54.1m / Invested Capital 294.5m)
WACC = 5.79% (E(871.9m)/V(905.2m) * Re(5.99%)) + (D(33.3m)/V(905.2m) * Rd(0.81%) * (1-Tc(0.20)))
Shares Correlation 5-Years: -35.40 | Cagr: 0.0%
Discount Rate = 5.99% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.90% ; FCFE base≈81.2m ; Y1≈104.0m ; Y5≈193.0m
Fair Price DCF = 786.2 (DCF Value 3.26b / Shares Outstanding 4.15m; 5y FCF grow 30.0% → 3.0% )
Revenue Correlation: N/A | Revenue CAGR: 0.0%
Revenue Growth Correlation: 31.07%
EPS Correlation: 38.35 | EPS CAGR: -1.91%
EPS Growth Correlation: 63.74%